Scarica l'app Stockscreener
2.77
4.48%
-0.13
Dopo l'orario di chiusura:
2.82
0.05
+1.81%
Precedente Chiudi:
$2.90
Aprire:
$2.92
Volume 24 ore:
36,258
Relative Volume:
0.52
Capitalizzazione di mercato:
$11.75M
Reddito:
-
Utile/perdita netta:
$-18.85M
Rapporto P/E:
-0.4282
EPS:
-6.4686
Flusso di cassa netto:
$-29.75M
1 W Prestazione:
-21.08%
1M Prestazione:
-1.77%
6M Prestazione:
-44.38%
1 anno Prestazione:
+812.08%
Intervallo 1D:
$2.70
$2.95
Intervallo di 1 settimana:
$2.6601
$3.50
Portata 52W:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Nome
Cellectar Biosciences Inc
Settore
Industria
Telefono
(608) 441-8120
Indirizzo
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
2.77 | 12.30M | 0 | -18.85M | -29.75M | -6.4686 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Ripresa | Ladenburg Thalmann | Buy |
| 2020-07-01 | Iniziato | Oppenheimer | Outperform |
| 2020-01-21 | Ripresa | ROTH Capital | Buy |
| 2019-09-13 | Iniziato | ROTH Capital | Buy |
| 2016-12-21 | Iniziato | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cellectar (CLRB) Marks Significant Achievements in 2025 - GuruFocus
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Cellectar (CLRB) Q4 2025 Earnings Call Transcript - The Globe and Mail
CLRB: Advanced late-stage pipeline, improved financials, and set up for major regulatory milestones in 2026 - TradingView
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Investing News Network
CLRB: Advanced regulatory progress, reduced losses, and extended cash runway position for key 2026 milestones - TradingView
Cellectar Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows - AlphaStreet News
CLRB: Net loss narrowed as pipeline advanced toward key regulatory and clinical milestones - TradingView
Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView
Cellectar (NASDAQ: CLRB) halves 2025 loss while pushing key cancer drugs - Stock Titan
Iopofosine progress at Cellectar (NASDAQ: CLRB) with pivotal WM data and FDA path - Stock Titan
Cellectar Biosciences, Inc. Advances Iopofosine I-131 Submission for Waldenström Macroglobulinemia and Initiates Phase 1b Study of CLR 125 in Triple Negative Breast Cancer - Quiver Quantitative
Cancer-drug firm gets FDA breakthrough tag, yet lost $21.8M in 2025 - Stock Titan
Insights into Cellectar Biosciences's Upcoming Earnings - Benzinga
Cellectar Biosciences Inc expected to post a loss of $2.02 a shareEarnings Preview - TradingView
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Rate Cut: Is Cellectar Biosciences Inc currently under institutional pressureJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - baoquankhu1.vn
CLRB SEC FilingsCellectar Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analyst Upgrade: Will Cellectar Biosciences Inc benefit from rising consumer demandMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
CLRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Nasdaq Moves: How cyclical is Cellectar Biosciences Incs revenue streamMarket Performance Recap & High Accuracy Trade Alerts - baoquankhu1.vn
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - Investing News Network
CLRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Bear: What drives Cellectar Biosciences Inc.’s stock priceQuarterly Profit Review & AI Forecasted Entry and Exit Points - mfd.ru
Gap Down: What are Cellectar Biosciences Incs growth leversJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition - AOL.com
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com
Cellectar Biosciences Expands Global Intellectual Property Estate - Investing News Network
Cellectar Biosciences Expands Global Intellectual Property Portfolio Ahead of Iopofosine I 131 Marketing Approval for Waldenström Macroglobulinemia - Quiver Quantitative
Will Cellectar Biosciences Inc. benefit from rising consumer demandCEO Change & Comprehensive Market Scan Insights - mfd.ru
Analysis Recap: Whats the fair value of Cellectar Biosciences Inc stockQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Bleichroeder group discloses 4.61% CLRB stake in amended ownership filing - Stock Titan
Is Cellectar Biosciences Inc. stock risky to hold now2025 Top Gainers & Advanced Swing Trade Entry Alerts - mfd.ru
How cyclical is Cellectar Biosciences Inc.’s revenue streamEarnings Miss & Verified Technical Signals - mfd.ru
Is Cellectar Biosciences Inc. a top pick in the sector2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru
Will Cellectar Biosciences Inc. stock reach all time highs in 2025 - mfd.ru
Rosalind group discloses 5.5% Cellectar (CLRB) stake with conversion caps - Stock Titan
Can Cellectar Biosciences Inc weather a recession2025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Can Cellectar Biosciences Inc. disrupt its industryQuarterly Growth Report & Real-Time Volume Spike Alerts - mfd.ru
Risk Report: Is BioLineRx Ltd Depositary Receipt a top pick in the sectorInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Weekly Trades: Is Cellectar Biosciences Inc a top pick in the sector - baoquankhu1.vn
What’s the fair value of Cellectar Biosciences Inc. stock - mfd.ru
Stock Analysis: What is the Moat Score of NAMIJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Cellectar Biosciences Inc disrupt its industryJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
What catalysts could drive Cellectar Biosciences Inc. stock higherMarket Insider Reports & Low Risk Trading Ideas - Bollywood Helpline
Is Cellectar Biosciences Inc currently under institutional pressure2025 Earnings Impact & High Return Trade Guides - baoquankhu1.vn
Fundamentals Check: How volatile is Cellectar Biosciences Inc stockWeekly Gains Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Ideas Watch: How cyclical is Cellectar Biosciences Incs revenue streamWeekly Stock Analysis & Accurate Intraday Trade Tips - baoquankhu1.vn
Cellectar Biosciences Inc Azioni (CLRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cellectar Biosciences Inc Azioni (CLRB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
11,638 |
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):